Given the multifaceted role of PKC in glioma biology, targeting its isoforms offers a potential therapeutic approach to disrupt tumor growth and invasion.312,313 Inhibiting PKC-mediated pathways could improve treatment efficacy, providing a rationale for further exploration of the use of PKC inhibitors in GBM therapy. This evidence concerns the gene PRRT2 and central nervous system cancer.